Navigation

Researchers at UCD

researcher

William Gallagher

Professor

School Of Biomolecular & Biomed Science
Conway Institute
Belfield
Dublin 4

Tel: 353 1 7166743
Email: william.gallagher@ucd.ie

Biography

Professor William Gallagher BSc PhD CBiol MSB


William Gallagher is Director of the UCD Conway Institute of Biomolecular and Biomedical Research, and Professor of Cancer Biology in the UCD School of Biomolecular & Biomedical Science. He is also the Director of the first Irish Cancer Society Collaborative Cancer Research Centre, BREAST-PREDICT, which will receive 7.5 million euro in funding from 2013 to 2018 (www.breastpredict.com). His primary research interests are in the areas of cancer biology and molecular therapeutics.

Prof. Gallagher originally graduated from the Department of Biochemistry, UCD in 1993 with a 1st Class Joint Honours degree in Molecular Genetics and Biochemistry. Subsequently, he obtained a PhD in Molecular and Cellular Biology from the Cancer Research UK Beatson Laboratories in Glasgow. In 1997, he moved to Paris to undertake a Marie Curie Individual Fellowship at Rhone-Poulenc Rorer (currently Sanofi-Aventis). Afterwards, he returned to Ireland upon receipt of an Enterprise Ireland Post-Doctoral Fellowship (1999-2000) and, subsequently, a Marie Curie Return Fellowship (2000-2001).

In 2001, he was employed in a permanent capacity as College Lecturer at UCD within the former Department of Pharmacology. In 2005, he was appointed Senior Lecturer within the UCD School of Biomolecular and Biomedical Science and was promoted to Associate Professor of Cancer Biology in 2006. In September 2009, Prof. Gallagher took up the position of Vice-Principal of Research and Innovation at the UCD College of Life Sciences, and was appointed a Conway Fellow at the UCD Conway Institute. In 2007, he co-founded OncoMark Ltd. (where he is currently Chief Scientific Officer), which is a private company centred on the development and application of biomarker panels and associated technologies, on both tissues and biological fluids (www.oncomark.com).

A major focus of Prof. Gallagher's research work is the identification and validation of candidate biomarkers of breast cancer and melanoma, with particular emphasis on translation of transcriptomic and proteomic datasets into clinically relevant assays. In addition, his team utilises lentiviral-based approaches to investigate the functional relevance of candidate tumour progression-associated genes at both in vitro and in vivo levels, as well as engages in preclinical evaluation of novel anti-cancer agents. 

Prof. Gallagher has a track record of success in attracting European funding and has participated as a co-ordinator/partner in several EU framework programmes. He previously co-ordinated 3 Industry-Academia Partnership (& Pathways) Programmes in breast cancer (Target-Breast), melanoma (Target-Melanoma), and prostate cancer (FAST-PATH). He currently co-ordinates the FP7 programmes, SYS-MEL, which uses systems medicine approaches to develop new diagnostic solutions in melanoma (www.sysmel.com), and RATHER, which focuses on new rationalised therapy options for difficult-to-treat breast cancer (www.rather.com).

Since 1999, he has attracted more than 65 million euro in research funding from both national and external sources, over 28 million euro of this as a principal applicant. Together with Prof. John Crown, Prof. Gallagher was also co-PI on a major Science Foundation Ireland-funded Strategic Research Cluster, Molecular Therapeutics of Cancer Ireland, which ran from 2009 to 2014 (www.mtci.ie). This was one of the most extensive organ-independent programmes in translational cancer research within Ireland, involving extensive collaboration with  pharmaceutical, biotech and imaging companies.

Prof. Gallagher has received a number of awards based on his research work to date, including the BACR/AstraZeneca Young Scientist Frank Rose Award in 2004, the St. Luke's Silver Medal Award in 2008, and the RAMI Doctors award in Oncology in 2013. Prof. Gallagher has had productive collaborative interactions with a variety of other industrial partners throughout his research, and has filed multiple patents.


Research Links:  Research in SBBS   |  Mechanisms of Disease (Cancer) Research in SBBS  |  Model Organisms Research in SBBS  |  Cancer Biology & Therapeutics Lab  |  BREAST-PREDICT  |  Oncomark Limited

Professional

Honours and Awards

Year: 2013.
Title: RAMI Doctor Awards 2013, Winner in Oncology Section
Year: 2011.
Title: NovaUCD Innovation Award 2011
Year: 2008.
Title: JMS Doctor Awards 2008 - Winner in Oncology Section
Year: 2008.
Title: 33rd St. Luke's Lecture and Silver Medal 2008
Year: 2007.
Title: JMS Doctor Awards 2007 - Finalist in Oncology Section
Year: 2006.
Title: JMS Doctor Awards 2006 - Finalist in Oncology Section
Year: 2005.
Title: JMS Doctor Awards 2005 - Finalist in Oncology Section
Year: 2004.
Title: BACR/AstraZeneca
Year: 2003.
Title: JMS Doctor Award
Year: 2000.
Title: BACR/Hamilton-Fairley
Year: 2000.
Title: Marie Curie Return Fellowship
Year: 1999.
Title: Enterprise Ireland Postdoctoral Fellowship
Year: 1997.
Title: Marie Curie Research Training Grant
Year: 1996.
Title: Bristol-Myers Squibb Oncology Award
Year: 1993.
Title: Cancer Research Campaign PhD Studentship
Year: 0.
Title: First Position in Molecular Genetics
Year: 1993.
Title: Second Position in Biochemistry Class
Year: 1992.
Title: Wellcome Trust Summer Vacation Scholarship
Year: 1989.
Title: Mount Sion CBS Gold Medal Award
Year: 0.
Title: Travel Award
Year: 0.
Title: Travel Award

Associations

Association: Irish Co-operative Oncology Research Group, Function/Role: Member and Collaborator
Association: Metastasis Research Society (Jan 2008 ¿ Present), Function/Role: member
Association: Royal Academy of Medicine in Ireland (Jan 2008 - Present), Function/Role: member
Association: The Biochemical Society (Date of election 01-10-93), Function/Role: *
Association: American Association for Cancer Research Active Member (Jan 2004 Present), Function/Role: *
Association: Associate Editor of MCFA News (Oct 2002 Present), Function/Role: *
Association: Deputy Co-Ordinator of the Conway Institute Cancer Biology Group (Jul 2002-Present), Function/Role: *
Association: Expert on the following Conway Institute Core Activity Units: Transcriptomics/ Bioinformatics/Information Technology (July 2002 Present) , Function/Role: *
Association: Lead Co-Ordinator of the Conway Institute Cancer Biology Group (Oct 2001 to Jul 2002), Function/Role: *
Association: Member of Conway Institute Transcriptomics Management Committee (Jan 2000 to Dec 2001), Function/Role: *
Association: Council Member of the Irish Association for Cancer Research (Date of election 14-04-00), Function/Role: *
Association: Co-Ordinator of the Marie Curie Fellowship Association Irish Section (since 1999), Function/Role: *
Association: Irish Association for Cancer Research (since 1999), Function/Role: *
Association: Marie Curie Fellowship Association (Date of election 28-04-99), Function/Role: *
Association: Institute of Biology (Date of election 25-03-99), Function/Role: *
Association: British Association for Cancer Research (Date of election 02-04-95), Function/Role: *

Patents

Patent WO2016042164 : A method of predicting risk of recurrence of cancer
Patent 13150937.4 : A peptide conjugate suitable for use as an anti-cancer agent.
Patent S2007/0882 : Method and system for image analysis
Patent US20040005646 : Use of the S2-6 gene product as a diagnostic marker for cancer detection.
Patent PCT/GB2006/0007 : Markers for Melanoma - UK Patent Application
Patent GB 0604370.7 : Markers for Melanoma
Patent PCT/US07/68619 : Methods and compositions for identifying and using p21-regulated proteins.
Patent 03/080627 : Compounds useful as photodynamic therapeutic agents.
Patent WO0022120 : (MBP1) polypeptides capable of interacting with oncogenic mutants of the p53 protein.
     

Committees

Committee : Breast Cancer Campaign Scientific Advisory Board
Committee : Irish Cancer Society Research Capacity Building Committee
Committee : Irish Cancer Society Research Fellowship Committee
Committee : Breast Cancer Campaign Gap Analysis Committee
Committee : University Research Strategy Board (2009-Present)
Committee : Member of Charles Institute Buildings Subcommittee (2008-Present)
Committee : Chairperson for UCD Seed Funding Review Panel - Programme 1/Strand 2 (2009)
Committee : Member of UCD Seed Funding Review Panel (2008)
Committee : UCD Research Computing Steering Group
Committee : SFI Cancer Committee
Committee : PRTLI Imaging Initiative
Committee : Conway Institute Cancer Biology Group
Committee : Conway Institute Cancer Biology Group
Committee : Conway Institute subgroups, including Transcriptomics, Proteomics, Bioinformatics and Histology
Committee : Health Research Board: Molecular, Cellular and Developmental Biology Committee
Committee : Health Research Board: Genomics, Proteomics and Human Disease Committee
Committee : Enterprise Ireland Basic Research Grant Committee

Employment

Employer: UCD
Position: Director UCD Conway Institute of Biomolecular and Biomedical Science/ Director of Irish Cancer Society Collaborative Cancer Research Centre BREAST-PREDICT
Employer: U.C.D
Position: Professor of Cancer Biology
Employer: AVENTIS Pharma, France
Position: Marie Curie Research Fellow
Employer: University College Dublin
Position: Enterprise Ireland Research Fellow
Employer: Conway Institute
Position: Core Investigator
Employer: Marie Curie Fellowship Association
Position: National Co-Ordinator
Employer: University College Dublin
Position: Marie Curie Return Fellow
Employer: University College Dublin
Position: College Lecturer
Employer: Conway Institute
Position: Lead Co-ordinator
Employer: Conway Institute
Position: Deputy Co-ordinator
Employer: U.C.D.
Position: Associate Professor of Cancer Biology

Education

Year 1993 Institution: University College Dublin
Qualification: BSc Subject:
Year 1996 Institution: University of Glasgow, Scotland
Qualification: PhD Subject:

Languages

English:
Irish:
French:
German:
 

Outreach Activities

I also participate in outreach activities to primary and secondary level students, with a view to fostering an interest in science.
   

Publications

Books

Foley, R. and DiFranco, M. and Bryan, K. and Rexhepaj, E. and Mulrane, L. and Watson, R.W. and Cunningham, P. and Gallagher, W.M. (2008) Automated image analysis approaches in histopathology. : IGI Global. [DOI] [Details]

Book Chapters

Cooney, H. C. M. and Gallagher, W. M.; (2011) 'Fibulins and their role in the ECM' In: Margareta M. Mueller and Norbert E. Fusenig (eds). Tumour-Associated Fibroblasts and Their Matrix: Tumor Stroma. Unknown: Spinger Science+Business Media B. V. , pp.159-174 [Details]
Collins, B. C., Lau, T. Y. K., Pennington, S. R., and Gallagher, W. M. ; (2011) 'Differential proteomics incorporating iTRAQ labelling and multi-dimensional separations' In: Jean-Charles Gautier (eds). Methods in Molecular Biology - Drug Safety Evaluation. N/A: Humana Press. , pp.369-384 Available Online [DOI] [Details]
Lau, T. Y. K., Collins, B. C., Stone, P., Tang, N., Gallagher, W. M., and Pennington, S. R. ; (2011) 'Absolute quantification of toxicological biomarkers via multiple reaction monitoring' In: Gautier, J.-C (eds). Methods in Molecular Medicine - Drug Safety Evaluation. New York: Humana Press. , pp.385-416 Available Online [Details]
Foley, R., Callanan, S., Gallagher, W., Cunningham, P.,; (2010) 'A Machine Learning System for Identifying Hypertrophy in Histopathology Images' In: Coyle, L. and Freyne, J (eds). Lecture Notes in Computer Science, Volume 6206 (AICS 2009). Berlin: Springer. , pp.72-81 Available Online [DOI] [Details]
Whelan, L. C., Cooney, H. C., Gallagher, W. M; (2009) 'Fibulins' In: Whelan, L. C., Cooney, H. C., Gallagher, W. M; (eds). Encyclopedia of Cancer, 2nd Edition. N/A: Springer-Verlag Berlin and Heidelberg GmbH & Co. [Details]
Foley, R., DiFranco, M., Bryan, K., Rexhepaj, E., Mulrane, L., Watson, W., Cunningham, P. and Gallagher, W. ; (2008) 'Automated Image Analysis Approaches in Histopathology' In: Foley, R., DiFranco, M., Bryan, K., Rexhepaj, E., Mulrane, L., Watson, W., Cunningham, P. and Gallagher, W. ; (eds). Handbook of Research on Systems Biology Applications in Medicine. Hershey, Pennsylvania: IGI Global. [Details]
Ryan, D., Mulrane, L., Rexhepaj, E., and Gallagher, W. M. ; (2008) 'Tissue microarrays and digital image analysis' In: Jean-Charles Gautier (eds). Methods in Molecular Medicine - Drug Safety Evaluation. Humana Press: N/A. Available Online [Details]
Foley, R., DiFranco, M., Bryan, K., Rexhepaj, E., Mulrane, L., Watson R. W., Cunningham, P., Gallagher, W. M.; (2008) 'Automated image analysis approaches in histopathology' In: Foley, R., DiFranco, M., Bryan, K., Rexhepaj, E., Mulrane, L., Watson R. W., Cunningham, P., Gallagher, W. M.; (eds). Handbook of Research on Systems Biology Applications in Medicine. Berlin, Germany: Andriani Daskalaki, Max Planck Institute for Molecular Genetics. , pp.826-849 [Details]
Kelly, C. M. A., Ryan, D., Penny, S., Gallagher, W. M. ; (2008) 'Systematic validation of breast cancer biomarkers using tissue microarrays: from construction to image analysis' In: Kelly, C. M. A., Ryan, D., Penny, S., Gallagher, W. M. ; (eds). Volume 1 of Cancer Diagnosis, Therapy, and Prognosis. N/A: M. A. Hayat. , pp.235-250 [Details]
 

Peer Reviewed Journals

Grossi M, Morgunova M, Cheung S, Scholz D, Conroy E, Terrile M, Panarella A, Simpson JC, Gallagher WM, O'Shea DF. (2016) 'Lysosome triggered near-infrared fluorescence imaging of cellular trafficking processes in real time'. Nature Communications, . [Details]
Walsh L, Gallagher WM, O'Connor DP, Ní Chonghaile T. (2016) 'Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer'. Expert Review of Molecular Diagnostics, . [Details]
Michaut M, Chin SF, Majewski I, Severson TM, Bismeijer T, de Koning L, Peeters JK, Schouten PC, Rueda OM, Bosma AJ, Tarrant F, Fan Y, He B, Xue Z, Mittempergher L, Kluin RJ, Heijmans J, Snel M, Pereira B, Schlicker A, Provenzano E, Ali HR, Gaber A, O'Hurley G, Lehn S, Muris JJ, Wesseling J, Kay E, Sammut SJ, Bardwell HA, Barbet AS, Bard F, Lecerf C, O'Connor DP, Vis DJ, Benes CH, McDermott U, Garnett MJ, Simon IM, Jirström K, Dubois T, Linn SC, Gallagher WM, Wessels LF, Caldas C, Bernards R. (2016) 'Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer'. Scientific Reports, . [Details]
Foth M, Wouters J, de Chaumont C, Dynoodt P, Gallagher WM. (2016) 'Prognostic and predictive biomarkers in melanoma: an update'. Expert Review of Molecular Diagnostics, . [Details]
O'Callaghan DS, Rexhepaj E, Gately K, Coate L, Delaney D, O'Donnell DM, Kay E, O'Connell F, Gallagher WM, O'Byrne KJ. (2015) 'Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer'. European Respiratory Journal, . [Details]
Szwej, E. and Devocelle, M. and Kenny, S. and Guzik, M. and O'Connor, S. and Nikodinovic-Runic, J. and Radivojevic, J. and Maslak, V. and Byrne, A.T. and Gallagher, W.M. and Zulian, Q.R. and Zinn, M. and O'Connor, K.E. (2015) 'The chain length of biologically produced (R)-3-hydroxyalkanoic acid affects biological activity and structure of anti-cancer peptides'. Journal of Biotechnology, 204 :7-12. Available Online [DOI] [Details]
Murphy L, Prencipe M, Gallagher WM, Watson RW (2015) 'Commercialized biomarkers: new horizons in prostate cancer diagnostics'. Expert Review of Molecular Diagnostics, 15 (4):491-503. [DOI] [Details]
van den Hurk K, Balint B, Toomey S, O'Leary PC, Unwin L, Sheahan K, McDermott EW, Murphy I, van den Oord JJ, Rafferty M, FitzGerald DM, Moran J, Cummins R,MacEneaney O, Kay EW, O'Brien CP, Finn SP, Heffron CC, Murphy M, Yela R, Power DG, Regan PJ, McDermott CM, O'Keeffe A, Orosz Z, Donnellan PP, Crown JP, Hennessy BT, Gallagher WM. (2015) 'High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients'. Melanoma Research, 25 (3):189-199. [DOI] [Details]
Mischak H, Critselis E, Hanash S, Gallagher WM, Vlahou A, Ioannidis JP. (2015) 'Epidemiologic design and analysis for proteomic studies: a primer on -omic technologies'. American Journal of Epidemiology, 181 (9):635-647. [DOI] [Details]
Nelson L, McKeen HD, Marshall A, Mulrane L, Starczynski J, Storr SJ, Lanigan F, Byrne C, Arthur K, Hegarty S, Ali AA, Furlong F, McCarthy HO, Ellis IO, Green AR, Rakha E, Young L, Kunkler I, Thomas J, Jack W, Cameron D, Jirström K,Yakkundi A, McClements L, Martin SG, Gallagher WM, Dunn J, Bartlett J, O'Connor D, Robson T (2015) 'FKBPL: a marker of good prognosis in breast cancer'. Oncotarget, 6 (14):12209-12223. [Details]
Vizoso M, Ferreira HJ, Lopez-Serra P, Carmona FJ, Martínez-Cardús A, Girotti MR, Villanueva A, Guil S, Moutinho C, Liz J, Portela A, Heyn H, Moran S, Vidal A,Martinez-Iniesta M, Manzano JL,Fernandez-Figueras MT, Elez E, Muñoz-Couselo E,Botella-Estrada R, Berrocal A, Pontén F, Oord Jv, Gallagher WM, Frederick DT,Flaherty KT, McDermott U, Lorigan P, Marais R, Esteller M (2015) 'Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR'. Nature Medicine, 21 (7):741-750. [Details]
Lanigan F, Brien GL, Fan Y, Madden SF, Jerman E, Maratha A, Aloraifi F, Hokamp K, Dunne EJ, Lohan AJ, Flanagan L, Garbe JC, Stampfer MR, Fridberg M, Jirstrom K,Quinn CM, Loftus B, Gallagher WM, Geraghty J, Bracken AP (2015) 'Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node-negative breast cancer patients'. FEBS Journal, 282 (18):3455-3473. [Details]
O'Hurley G, Busch C, Fagerberg L, Hallström BM, Stadler C, Tolf A, Lundberg E,Schwenk JM, Jirström K, Bjartell A, Gallagher WM, Uhlén M, Pontén F (2015) 'Analysis of the Human Prostate-Specific Proteome Defined by Transcriptomics and Antibody-Based Profiling Identifies TMEM79 and ACOXL as Two Putative, Diagnostic Markers in Prostate Cancer'. PLoS ONE, 10 (8):e0133449. [Details]
Prencipe M, O'Neill A, O'Hurley G, Nguyen LK, Fabre A, Bjartell A, Gallagher WM, Morrissey C, Kay EW, Watson RW. (2015) 'Relationship between serum response factor and androgen receptor in prostate cancer'. Prostate, 75(15) (15):1704-1717. [Details]
O'Brien K, Lowry MC, Corcoran C, Martinez VG, Daly M, Rani S, Gallagher WM,Radomski MW, MacLeod RA, O'Driscoll L (2015) 'miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity'. Oncotarget, 6 (32):32774-32789. [Details]
Lowry MC, Gallagher WM, O'Driscoll L (2015) 'The Role of Exosomes in Breast Cancer'. Clinical Chemistry, . [Details]
Denecker, G. and Vandamme, N. and Akay, O. and Koludrovic, D. and Taminau, J. and Lemeire, K. and Gheldof, A. and De Craene, B. and Van Gele, M. and Brochez, L. and Udupi, G. M. and Rafferty, M. and Balint, B. and Gallagher, W. M. and Ghanem, G. and Huylebroeck, D. and Haigh, J. and van den Oord, J. and Larue, L. and Davidson, I. and Marine, J-C and Berx, G. (2014) 'Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression'. Cell Death and Differentiation, 21 (8):1250-1261. [DOI] [Details]
Jarzabek MA, Amberger-Murphy V, Callanan JJ, Gao C, Zagozdzon AM, Shiels L, Wang J, Ligon KL, Rich BE, Dicker P, Gallagher WM, Prehn JH, Byrne AT. (2014) 'Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models'. British Journal of Cancer, 111 (12):2275-2286. [DOI] [Details]
Duffy MJ, Synnott NC, McGowan PM, Crown J, O'Connor D, Gallagher WM. (2014) 'p53 as a target for the treatment of cancer'. Cancer Treatment Reviews, 40 (10):1153-1160. [DOI] [Details]
Stephen F Madden, Colin Clarke, Britta Stordal, Mark S Carey, Russell Broaddus, William M Gallagher, John Crown, Gordon B Mills and Bryan T Hennessy. (2014) 'OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets'. Molecular Cancer, 13 (241). [Details]
O¿Leary, P. C., Terrile, M., Bajor, M., Gaj, P., Hennessy, B. T., Mills, G. B., Zagozdzon, A., O¿Connor, D. P., Brennan, D. J., Connor, K., Li, J., Gonzalez-Angulo, A., Sun, H., Pu, J., Pontén, F., Uhlén, M., Jirström, K., Nowis, D. A., Crown, J. P., Zagozdzon, R., and Gallagher, W. M. (2014) 'Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer'. Breast Cancer Research, 16 (4):R79. [Details]
O'Hurley, Gillian and Prencipe, Maria and Lundon, Dara and O'Neill, Amanda and Boyce, Susie and O'Grady, Anthony and Gallagher, William M. and Morrissey, Colm and Kay, Elaine W. and Watson, R. William G. (2014) 'The Analysis of Serum Response Factor Expression in Bone and Soft Tissue Prostate Cancer Metastases'. Prostate, 74 (3):306-313. [DOI] [Details]
O'Hurley, Gillian and Daly, Etain and O'Grady, Anthony and Cummins, Robert and Quinn, Cecily and Flanagan, Louise and Pierce, Aisling and Fan, Yue and Lynn, Miriam A. and Rafferty, Mairin and Fitzgerald, Dara and Ponten, Fredrik and Duffy, Michael J. and Jirstrom, Karin and Kay, Elaine W. and Gallagher, William M. (2014) 'Investigation of molecular alterations of AKT-3 in triple-negative breast cancer'. Histopathology, 64 (5):660-670. [DOI] [Details]
Mulrane, Laoighse and Klinger, Rut and McGee, Sharon F. and Gallagher, William M. and O'Connor, Darran P. (2014) 'microRNAs: a new class of breast cancer biomarkers'. Expert Review of Molecular Diagnostics, 14 (3):347-363. [DOI] [Details]
O'Hurley, Gillian and Sjosted, Evelina and Rahman, Arman and Li, Bo and Kampf, Caroline and Ponten, Fredrik and Gallagher, William M. and Lindskog, Cecilia (2014) 'Garbage in, garbage out: A critical evaluation of strategies used for validation of immunohistochemical biomarkers'. Molecular oncology, 8 (4, SI):783-798. [DOI] [Details]
Madden S. F., Clarke C., Aherne S. T., Gaule P., O'Donovan N., Crown J., Clynes M., Gallagher W.M. (2013) 'BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome'. Breast Cancer Research, 15 (4):R52. [Details]
Nyamundanda, G., Gormley, I.C., Fan,Y., Gallagher, W.M. and Brennan, L. (2013) 'MetSizeR: selecting the optimal sample size for metabolomic studies using an analysis based approach'. BMC Bioinformatics, . [DOI] Link to full text [Details]
Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, Hewitt S, Udupi GM, Gallagher WM, Wegner C, West BL, Wang-Gillam A, Goedegebuure P, Linehan DC, DeNardo DG. (2013) 'Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses'. Cancer Research, 73 (3):1128-1141. [DOI] [Details]
O'Connor S, Szwej E, Nikodinovic-Runic J, O'Connor A, Byrne AT, Devocelle M, O'Donovan N, Gallagher WM, Babu R, Kenny ST, Zinn M, Zulian QR, O'Connor KE (2013) 'The anti-cancer activity of a cationic anti-microbial peptide derived from monomers of polyhydroxyalkanoate'. Biomaterials, 34 (11):2710-2718. [DOI] [Details]
Prencipe M, Madden SF, O'Neill A, O'Hurley G, Culhane A, O'Connor D, Klocker H, Kay EW, Gallagher WM, Watson WR. (2013) 'Identification of transcription factors associated with castration-resistance: is the serum responsive factor a potential therapeutic target?'. Prostate, 73 (7):743-753. [DOI] [Details]
O Leary PC, Penny SA, Dolan RT, Kelly CM, Madden SF, Rexhepaj E, Brennan DJ, McCann AH, Pontén F, Uhlén M, Zagozdzon R, Duffy MJ, Kell MR, Jirström K, Gallagher WM (2013) 'Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer'. BMC Cancer, 13 (175). [DOI] [Details]
Rexhepaj E, Agnarsdóttir M, Bergman J, Edqvist PH, Bergqvist M, Uhlén M, Gallagher WM, Lundberg E, Ponten F. (2013) 'A texture based pattern recognition approach to distinguish melanoma from non-melanoma cells in histopathological tissue microarray sections'. PLoS ONE, 8 (5). [DOI] [Details]
Clarke C, Madden SF, Doolan P, Aherne ST, Joyce H, O' Driscoll L, Gallagher WM, Hennessy BT, Moriarty M, Crown J, Kennedy S, Clynes M (2013) 'Correlating transcriptional networks to breast cancer survival: A large-scale coexpression analysis'. Carcinogenesis, . [Details]
Mulrane L, Madden SF, Brennan DJ, Gremel G, McGee SF, McNally S, Martin F, Crown JP, Jirström K, Higgins DG, Gallagher WM, O'Connor DP (2012) 'miR-187 Is an Independent Prognostic Factor in Breast Cancer and Confers Increased Invasive Potential In Vitro'. Clinical Cancer Research, . [Details]
O'Connor, AE McGee MM, Likar Y, Ponomarev V, Callanan JJ, O'Shea DF, Byrne AT, Gallagher WM (2012) 'Mechanism of Cell Death Mediated by a BF2-Chelated Tetraarylazadipyrromethene Photodynamic Therapeutic'. International Journal of Cancer, 130 (3):705-715. [Details]
Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, Coward JI, Schioppa T, Robinson SC, Gallagher WM, Galletta L; Australian Ovarian Cancer Study Group, Salako MA, Smyth JF, Hagemann T, Brennan DJ, Bowtell DD, Balkwill FR (2012) 'A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment'. Cancer research, 72 (1):66-75. [Details]
Brennan DJ, O'Connor DP, Laursen H, McGee SF, McCarthy S, Zagozdzon R, Rexhepaj E, Culhane AC, Martin FM, Duffy MJ, Landberg G, Ryden L, Hewitt SM, Kuhar MJ, Bernards R, Millikan RC, Crown JP, Jirstrom K, Gallagher WM (2012) 'The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ERα, and is an independent prognostic factor in node-negative breast cancer'. Oncogene, 31 (30):3483-3494. [DOI] [Details]
Geiger T, Madden SF, Gallagher WM, Cox J, Mann M (2012) 'Proteomic portrait of human breast cancer progression identifies novel prognostic markers'. Cancer Research, 72 (9):428-439. [Details]
Collins BC, Miller CA, Sposny A, Hewitt P, Wells M, Gallagher WM, Pennington SR (2012) 'Development of a pharmaceutical hepatotoxicity biomarker panel using a discovery to targeted proteomics approach'. Molecular & Cellular Proteomics, 11 (8):394-410. [Details]
Zagozdzon AM, O'Leary P, Callanan JJ, Crown J, Gallagher WM, Zagozdzon R (2012) 'Generation of a new bioluminescent model for visualisation of mammary tumour development in transgenic mice'. BMC Cancer, 12 (209). [Details]
Collins BC, Gallagher WM (2012) 'Focus on cancer proteomics'. Proteomics, 12 (13):2065-2066. [DOI] [Details]
Joyce CW, Murphy IG, Rafferty M, Ryan D, McDermott EW, Gallagher WM (2012) 'Tumor profiling using protein biomarker panels in malignant melanoma: application of tissue microarrays and beyond'. Expert Review of Proteomics, 9 (9):415-423. [DOI] [Details]
Vader P, van der Meel R, Symons MH, Fens MH, Pieters E, Wilschut KJ, Storm G, Jarzabek M, Gallagher WM, Schiffelers RM, Byrne AT (2011) 'Examining the role of Rac1 in tumor angiogenesis and growth: a clinically relevant RNAi-mediated approach'. Angiogenesis, 14 (4):457-466. [Details]
O'Donovan N, Byrne AT, O'Connor A E, McGee S, Gallagher W M, and Crown J (2011) 'Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells'. Investigational New Drugs, 29 (5):752-759. [Details]
Dahlman, A., Rexhepaj, E., Brennan, D. J., Gallagher, W. M., Gaber, A., Lindgren, A., Jirström, K., and Bjartell, A; (2011) 'Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis'. Modern Pathology, 24 (5):708-719. [Details]
Fitzpatrick, S. F., Tambuwala, M. M., Bruning, U., Schaible, B., Scholz, C. C., Byrne, A., O'Connor, A., Gallagher, W. M., Lenihan, C. R., Garvey, J. F., Howell, K., Fallon, P. G., Cummins, E. P., and Taylor, C. T. ; (2011) 'An intact canonical NF-kB pathway is required for inflammatory gene expression in pesponse to hypoxia'. Immunology, 186 (2):1091-1096. [Details]
Devitt, E. J., Power, K. A., Lawless, M. W., Browne, J. A., Gaora, P. O., Gallagher, W. M., and Crowe, J. ; (2011) 'Early proteomic analysis may allow noninvasive identification of hepatitis C response to treatment with pegylated interferon α-2b and ribavirin'. European Journal of Gastroenterology & Hepatology, 23 (2):177-183. [Details]
Holladay, C., Power, K., Sefton, M., O'Brien, T., Gallagher, W. M., and Pandit, A. ; (2011) 'Functionalized scaffold mediated interleukin-10 gene delivery significantly improves survival rates of stem cells in vivo'. Molecular Therapy, 19 (5):969-978. [Details]
Dasari, S., Chambers, M. C., Codreanu, S. G., Liebler, D. C., Collins, B. C., Pennington, S. R., Gallagher, W. M. and Tabb, D. L. ; (2011) 'Sequence tagging reveals unexpected modifications in toxicoproteomics'. Chemical research in toxicology, 24 (2):204-216. [Details]
Brennan, D. J., Laursen, H., O'Connor, D., Borgquist, S., Uhlén, M., Gallagher, W. M., Ponten, F., Millikan, R. C., Ryden, L., and Jirstrom, K.; (2011) 'Tumor specific HMG-CoA reductase expression in primary pre-menopausal breast cancer predicts response to tamoxifen'. Breast Cancer Research, 13 (1):R12. [Details]
Magnusson, K., de Wit. M., Brennan, D. J., Johnson, L. B., McGee, S. F., Lundberg, E., Naicker, K., Klinger, R., Kampf, C., Asplund, A., Wester, K., Gry, M., Bjartell, A., Gallagher, W.M., Rexhepaj, E., Kilpinen, S., Kallioniemi, O. P., Belt, E., Goos, J., Meijer, G., Birgisson, H., Glimelius, B., Borrebaeck, C. A., Navani, S., Uhlén, M., OʼConnor, D. P., Jirström, K., and Pontén, F. ; (2011) 'SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas'. American Journal of Surgical Pathology, 35 (7):937-948. [Details]
Gremel, G., Ryan, D., Rafferty, M., Lanigan, F., Hegarty, S., Lavelle, M., Murphy, I., Unwin, L., Joyce, C., Faller, W., McDermott, E.W., Sheahan, K., Ponten, F.,Gallagher W.M. ; (2011) 'Functional and prognostic relevance of the homeobox protein MSX2 in malignant melanoma'. British Journal of Cancer, 105 (4):565-574. [Details]
Coward J, Kulbe H, Chakravarty P, Leader D A, Vassileva V, Leinster D A, Thompson R, Schioppa T, Nemeth J A, Vermeulin J, Singh N, Avril N E, Cummings J, Rexhepaj E, Jirstrom K, Gallagher W M, Brennan D J, McNeish I A, Balkwill F R (2011) 'Interleukin-6 as a therapeutic target in human ovarian cancer'. Clinical Cancer Research, 17 (18):6083-6096. [Details]
van der Meel R, Symons M H, Kudernatsch R, Kok R J, Schifflers R M, Storm G, Gallagher W M, and Byrne A T (2011) 'The VEGF/Rho GTPase signalling pathway: a promising target for antiangiogenic and anti-invasion therapy'. Drug Discovery Today, 16 (5-6):219-228. [Details]
Fitzgerald, K. T., Holladay, C. A., McCarthy, C., Power, K. A., Pandit, A., and Gallagher, W. M.; (2011) 'Standardization of models and methods used to assess nanoparticles in cardiovascular applications'. Small, 7 (6):705-717. [Details]
Zagozdzon R, Gallagher WM, Crown, J (2011) 'Truncated HER2: implications for HER2-targeted therapeutics'. Drug Discovery Today, 16 (17-18):812-816. [Details]
Johnston O, Cassidy H, O'Connell S, O'Riordan A, Gallagher W, Maguire PB, Wynne K, Cagney G, Ryan MP, Conlon PJ, McMorrow T (2011) 'Identification of β2-microglobulin as a urinary biomarker for chronic allograft nephropathy using proteomic methods'. Proteomics, 5 (7-8):422-431. [DOI] [Details]
O'Neill A.J., Prencipe M., Dowling C., Fan Y., Mulrane L., Gallagher W.M., O'Connor D., O'Connor R., Devery A., Corcoran C., Rani S., O¿Driscoll L., Fitzpatrick J., R., Watson R.W.G. ; (2011) 'Characterisation and Manipulation of Docetaxel Resistant Prostate Cancer Cell Lines'. MOL CANCER, . [Details]
DeNardo, DG,Brennan, DJ,Rexhepaj, E,Ruffell, B,Shiao, SL,Madden, SF,Gallagher, WM,Wadhwani, N,Keil, SD,Junaid, SA,Rugo, HS,Hwang, ES,Jirstrom, K,West, BL,Coussens, LM; (2011) 'Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy'. Journal of Cancer, 1 :54-67. [DOI] [Details]
Johnston, O,Cassidy, H,O'Connell, S,O'Riordan, A,Gallagher, W,Maguire, PB,Wynne, K,Cagney, G,Ryan, MP,Conlon, PJ,McMorrow, T; (2011) 'Identification of beta 2-microglobulin as a urinary biomarker for chronic allograft nephropathy using proteomic methods'. Proteomics Clinical Applications, 5 :422-431. [DOI] [Details]
Dowling, DP,Miller, IS,Ardhaoui, M,Gallagher, WM; (2011) 'Effect of Surface Wettability and Topography on the Adhesion of Osteosarcoma Cells on Plasma-modified Polystyrene'. Biomaterials, 26 :327-347. [DOI] [Details]
Power KA, Grad S, Rutges JP, Creemers LB, van Rijen MH, O'Gaora P, Wall JG, Alini M, Pandit A, Gallagher WM (2011) 'Identification of cell surface-specific markers to target human nucleus pulposus cells: expression of carbonic anhydrase XII varies with age and degeneration'. Arthritis Rheumatology, 63 (12):3876-3886. [DOI] [Details]
Maher SG, McDowell DT, Collins BC, Muldoon C, Gallagher WM, Reynolds JV (2011) 'Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation'. Annals of Surgery, 254 (5):809-816. [Details]
O'Neill AJ, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher WM, O'Connor D, O'Connor R, Devery A, Corcoran C, Rani S, O'Driscoll L, Fitzpatrick JM, Watson RW (2011) 'Characterisation and manipulation of docetaxel resistant prostate cancer cell lines'. MOL CANCER, 10 (126). [Details]
Sernbo S, Gustavsson E, Brennan DJ, Gallagher WM, Rexhepaj E, Rydnert F, Jirstrom K, Borrebaeck CA, Ek S (2011) 'The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation'. BMC Cancer, 11 (405). [Details]
Lindsay, C. R., Lawn, S., Campbell, A. D., Faller, W. J., Rambow, F., Mort, R. L., Timpson, P., Li, A., Cammareri, P., Ridgway, R. A., Morton, J. P., Doyle, B., Hegarty, S., Rafferty, R., Murphy, I. G., McDermott, E. W., Sheahan, K., Pedone, K., Finn, A. J., Groben, P. A., Thomas, N. E., Hao, H., Carson, C., Norman, J. C., Machesky, L. M., Gallagher, W. M., Jackson, I. J., Van Kempen, L., Beermann, F., Der, C., Larue, L., Welch, H. C., Ozanne, B. W. Sansom, O. J. ; (2011) 'P-Rex1 is required for efficient melanoblast migration and melanoma metastasis'. Nature Communications, . [Details]
Hams E, Saunders SP, Cummins EP, O'Connor A, Tambuwala MT, Gallagher WM, Byrne A, Campos-Torres A, Moynagh PM, Jobin C, Taylor CT, Fallon PG; (2011) 'The hydroxylase inhibitor dimethyloxallyl glycine attenuates endotoxic shock via alternative activation of macrophages and IL-10 production by B1 cells'. Shock, 36 (3):295-302. [Details]
Faller, WJ,Rafferty, M,Hegarty, S,Gremel, G,Ryan, D,Fraga, MF,Esteller, M,Dervan, PA,Gallagher, WM; (2010) 'Metallothionein 1E is methylated in malignant melanoma and increases sensitivity to cisplatin-induced apoptosis'. Melanoma Research, 20 :392-400. [DOI] [Details]
van der Meel, R., Gallagher, W. M., Oliveira, S., O'Connor, A. E., Schiffelers, R., and Byrne, A. T; (2010) 'Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies'. Drug Discovery Today, 15 (3/4):102-114. [Details]
Hoffmann, D., Adler, M., Vaidya, V., Rached, E., Mulrane, L., Gallagher, W. M., Callanan, J. J., Gautier, J. C., Matheis, K., Staedtler, F., Dieterle, F., Brandenburg, A., Sposny, A., Hewitt, P., Ellinger-Ziegelbauer, H., Bonventre, J. V., Dekant, W., and Mally, A.; (2010) 'Performance of novel kidney biomarkers in preclinical toxicity studies'. Toxicological sciences : an official journal of the Society of Toxicology, 116 (1):8-22. [Details]
Brennan, D. J., Brandstedt, J., Rexhepaj, E., Foley, M., Ponten, F., Uhlen, M., Gallagher, W. M., O'Connor, D. P., O'Herlihy, C., and Jirstrom, K; (2010) 'Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer'. BMC Cancer, 10 :125. [Details]
Collins, B. C., Sposny, A., McCarthy, D., Brandenburg, A., Woodbury, R., Pennington, S. R., Gautier, J. C., Hewitt, P., and Gallagher, W. M; (2010) 'Use of SELDI MS to discover and identify potential biomarkers of toxicity in InnoMed PredTox: A multi-site, multi-compound study'. Proteomics, 10 (8):1592-1608. [Details]
Ryan, D., Rafferty, M., Hegarty, S., Leary, P. O., Faller, W., Gremel, G., Bergqvist, M., Agnarsdottir, M., Strömberg, S., Kampf, C., Pontén, F., Millikan, R. C., Dervan, P. A., and Gallagher, W. M; (2010) 'Topoisomerase I amplification in melanoma is associated with more advanced tumours and poor prognosis'. Pigment Cell & Melanoma Research, 23 (4):542-553. [Details]
Lanigan, F., Gremel, G., Hughes, R., Brennan, D. J., Martin, F., Jirström, K., and Gallagher, W. M.; (2010) 'Homeobox transcription factor Msx2 correlates with good prognosis in breast cancer patients and induces apoptosis in vitro'. Breast Cancer Research, 12 (4):59. [Details]
Power, KA, Fitzgerald, KT and Gallagher, WM. ; (2010) 'Examination of cell-host-biomaterial interactions via high-throughput technologies: A re-appraisal'. Biomaterials, 31 (26):6667-6674. [Details]
Whyte, J., Thornton, L., McNally, S., McCarthy, S., Lanigan, F., Gallagher, W. M., Stein, T., and Martin, F. ; (2010) 'PKCdelta regulates cell polarisation and proliferation restriction during mammary acinus formation'. Journal of Cell Science, 123 (19):3316-3328. [Details]
Dash, B. C., Rethore, G., Monaghan, M., Fitzgerald, K., Gallagher, W.M, and Pandit, A; (2010) 'The influence of size and charge of chitosan/polyglutamic acid hollow spheres on cellular internalization, viability and blood compatibility'. Biomaterials, 31 (32):8188-8197. [Details]
Ursini-Siegel, J., Cory, S., Zuo, D., Hardy, W. R., Rexhepaj, E., Lam, S., Schade, B., Jirstrom, K., Bjur, E., Piccirillo, C. A., DeNardo, D., Coussens, L. M., Brennan, D. J., Gallagher, W. M., Park, M., Pawson, T., Hallett, M. and Muller, W. J.; (2010) 'Receptor tyrosine kinase signaling in breast cancer cells inhibits the adaptive immune response to favor a pro-tumorigenic state'. Cancer Research, 70 (20):7776-7787. [Details]
Rexhepaj, E., Jirstrom, K., O'Connor, D. P., O'Brien, S. L., Landberg G., Duffy, M. J., Brennan, D. J., and Gallagher, W. M. ; (2010) 'Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer'. BMC Cancer, 10 :639. [Details]
Agnarsdottir, M, Sooman, L., Bolander, A., Strömberg, S., Rexhepaj, E., Bergqvist, M., Ponten, F., Gallagher, W.M., Lennartsson, J., Ekman, S., Uhlen, M., and Hedstrand, H. ; (2010) 'SOX10 expression in superficial spreading and nodular malignant melanomas'. Melanoma Research, 20 (6):468-478. [Details]
O'Neill K, Lyons SK, Gallagher WM, Curran KM, Byrne AT; (2010) 'Bioluminescent imaging: a critical tool in pre-clinical oncology research'. Journal of Pathology, 220 (3):317-327. [DOI] [Details]
Brennan, D. J., O'Connor, D. P., Rexhepaj, E., Ponten, F., and Gallagher, W. M. ; (2010) 'Antibody-based proteomics: fast-tracking molecular diagnostics in oncology'. Nature reviews. Cancer, 10 (9):605-617. [Details]
Miller, IS,Lynch, I,Dowling, D,Dawson, KA,Gallagher, WM; (2010) 'Surface-induced cell signaling events control actin rearrangements and motility'. Journal of Biomedical Materials Research - Part A, 93A :493-504. [DOI] [Details]
Mally A, Adler M, Hoffmann D, Ellinger-Ziegelbauer H, Hewitt P, Matheis K, Mulrane L, Gallagher WM, Callanan JJ, Suter L, Fountoulakis MM, Dekant W, ; (2010) 'Assessment of candidate biomarkers of drug-induced hepatobiliary injury in preclinical toxicity studies'. Toxicology Letters, 196 :1-11. [DOI] [Details]
Lau, TYK,Power, KA,Dijon, S,de Gardelle, I,McDonnell, S,Duffy, MJ,Pennington, SR,Gallagher, WM; (2010) 'Prioritization of candidate protein biomarkers from an in vitro model system of breast tumor progression toward clinical verification'. Journal of Proteome Research, 5 :1450-1459. Available Online [DOI] [Details]
Gallagher WM, Miller IS, Lynch I, Dowling D, Dawson KA, ; (2009) 'Surface-induced cell signaling events control actin rearrangements and motility'. Journal of Biomedical Materials Research - Part A, (NA). [DOI] [Details]
Koenig J, Gallagher WM, Tweats D, ; (2009) 'Omic profiling for drug safety assessment: current trends and public-private partnerships'. Drug Discovery Today, 14 (7-8):337-342. [Details]
Brennan, D. J., Ek, S., Doyle, E., Drew, T., Foley, M., Flannelly, G., O¿Connor, D. P., Gallagher, W. M., Kilpinen, S., Kallioniemi, O-P., Jirstrom, K., O¿Herlihy, C., and Borrebaeck, C. A. K. ; (2009) 'The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer'. European Journal of Cancer, 45 (8):1510-1517. [DOI] [Details]
Lanigan, F,McKiernan, E,Brennan, DJ,Hegarty, S,Millikan, RC,McBryan, J,Jirstrom, K,Landberg, G,Martin, F,Duffy, MJ,Gallagher, WM; (2009) 'Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer'. International Journal of Cancer, 124 (NA):2088-2097. [DOI] [Details]
McSherry, EA,Mcgee, SF,Jirstrom, K,Doyle, EM,Brennan, DJ,Landberg, G,Dervan, PA,Hopkins, AM,Gallagher, WM; (2009) 'JAM-A expression positively correlates with poor prognosis in breast cancer patients'. International Journal of Cancer, 125 (NA):1343-1351. [DOI] [Details]
Power, KA,McRedmond, JP,de Stefani, A,Gallagher, WM,Gaora, PO; (2009) 'High-Throughput Proteomics Detection of Novel Splice Isoforms in Human Platelets'. PLoS ONE, 4 (3):e5001. [DOI] [Details]
Gremel, G., Rafferty, M., Lau, T. Y. K., and Gallagher, W. M. ; (2009) 'Identification and functional validation of therapeutic targets for malignant melanoma'. Critical Reviews in Oncology Hematology, 72 :194-214. [Details]
O'Connor, A. E., Byrne, A. T., and Gallagher, W. M. ; (2009) 'Porphyrin and non-porphyrin photosensitizers in oncology: pre-clinical and clinical advances in photodynamic therapy'. Photochemistry and photobiology, 85 (5):1053-1074. [Details]
Patel, K. D., Duggan, S. P., Currid, C. A., Gallagher, W. M., McManus, R., Kelleher, D., Murphy, R. T., and Ryan, A. W. ; (2009) 'High sensitivity cytokine detection in acute coronary syndrome reveals up-regulation of interferon gamma and interleukin-10 post myocardial infarction'. Clinical Immunology, 133 (2):251-256. [Details]
Byrne, A. T., O'Connor, A. E., Hall, M., Murtagh, J., O'Neill, K., Curran, K. M., Mongrain, K., Rousseau, J. A., Lecomte, R., McGee, S., Callanan, J. J., O'Shea, D. F., and Gallagher, W. M.; (2009) 'Vascular targeted photodynamic therapy with BF2-chelated tetraaryl-azadipyromethene agents: A multi-modality molecular imaging approach to therapeutic assessment'. British Journal of Cancer, 101 (9):1565-1573. [Details]
Strömberg, S., Agnarsdóttir, M., Magnusson, K., Rexhepaj, E., Bolander, A., Lundberg, E., Asplund, A., Ryan, D., Rafferty, M., Gallagher, W. M., Uhlen, M., Bergqvist, M., and Ponten, F; (2009) 'Selective expression of Syntaxin-7 protein in benign melanocytes and malignant melanoma'. Journal of Proteome Research, 8 (4):1639-1646. [Details]
O Riordan A., Johnston O., McMorrow T., Wynne K., Maguire P., Hegarty J.E., McCormick A., Watson A.J., Cagney G., Gallagher W.M. and Ryan M.P. ; (2008) 'Identification of Apolipoprotein AI as a serum biomarker of chronic kidney disease in liver transplant recipients, using proteomic techniques'. Proteomics Clinical Applications, 2 (8):1338-1348. [Details]
Rexhepaj, E., Brennan, D. J., Holloway, P., Kay, E. W., McCann, A. H., Landberg, G., Duffy, M. J., Jirstrom, K., and Gallagher, W. M. ; (2008) 'Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of estrogen and progesterone receptor levels in breast cancer'. Breast cancer research : BCR, 10 (5):R89. [DOI] [Details]
Mulrane, L., Rexhepaj, E., Smart, V., Callanan, J. J., Orhan, D., Eldem, T., Mally, A., Schroeder, S., Meyer, K., Wendt, M., O'Shea, D., Gallagher, W. M., ; (2008) 'Creation of a digital slide and tissue microarray resource from a multi-institutional predictive toxicology study in the rat: An initial report from the PredTox group'. Experimental and Toxicologic Pathology, 60 (4-5):235-245. [Details]
Whelan LC, Power KA, McDowell DT, Kennedy PJ, Gallagher WM.; (2008) 'Applications of seldi technology in oncology'. Journal of cellular and molecular medicine, (NA). [DOI] [Details]
Gallagher WM, Mulrane L, Rexhepaj E, Penney S, Callanan JJ, ; (2008) 'Automated image analysis in histopathology: a valuable tool in medical diagnostics'. EXPERT REV MOL DIAGN, 6 (NA):707-725. [DOI] [Details]
Gallagher WM, Duffy MJ, McGowan PM, ; (2008) 'Cancer invasion and metastasis: changing views'. Journal of Pathology, 3 (NA):283-293. [DOI] [Details]
Brennan, D. J., Hewitt, S. M., Rexhepaj, E., O¿Brien, S. L., McSherry, E., O¿Connor, D. P., Fagan, A., Culhane, A. C., Higgins, D. G., Jirstrom, K., Millikan, R. C., Landberg, G., Duffy, M. J., and Gallagher, W. M. ; (2008) 'Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer'. Clinical Cancer Research, 14 (9):2681-2689. [DOI] [Details]
Lujambio A, Calin GA, Villanueva A, Ropero S, Sánchez-Céspedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ, Gallagher WM, Eccles SA, Croce CM, Esteller M; (2008) 'A microRNA DNA methylation signature for human cancer metastasis'. PNAS, 105 (36):13556-13561. [Details]
O'Riordan A, Johnston O, McMorrow T, Wynne K, Maguire P, Hegarty JE, McCormick A, Watson AJ, Cagney G, Gallagher WM, Ryan MR; (2008) 'Identification of Apolipoprotein AI as a serum biomarker of chronic kidney disease in liver transplant recipients, using proteomic techniques'. Proteomics Clinical Applications, 2 (9):1338-1348. [Details]
Gallagher WM, Brennan DJ, Rexhepaj E, O'Brien SL, McSherry E, O'Connor DP, Fagan A, Culhane AC, Higgins DG, Jirstrom K, Millikan RC, Landberg G, Duffy MJ, Hewitt SM, ; (2008) 'Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer'. Clinical Cancer Research, 9 (NA):2681-2689. [DOI] [Details]
O'Riordan, A,Johnston, O,McMorrow, T,Wynne, K,Maguire, P,Hegarty, JE,McCormick, A,Watson, AJ,Cagney, G,Gallagher, WM,Ryan, MR; (2008) 'Identification of Apolipoprotein AI as a serum biomarker of chronic kidney disease in liver transplant recipients, using proteomic techniques'. Proteomics, 2 :1338-1348. [DOI] [Details]
Gremel, G., Rafferty, M., Fitzgerald, K., Pizzato, S., Gallagher, W. M., ; (2008) 'Differential cell adhesion within an isogenic model of melanoma progression under shear flow conditions using a microfluidic cell-based assay'. Pigment Cell Melanoma Research, 21 (2):285-285. [Details]
Brennan, D. J., Gallagher, W. M., ; (2008) 'Prognostic ability of a panel of immunohistochemistry markers - retailoring of an 'old solution''. Breast Cancer Research, 10 (102):1-3. [DOI] [Details]
Lanigan, F., O'Connor, D., Martin, E., Gallagher, W. M., ; (2007) 'Common molecular links between mammary gland development and breast cancer'. Cellular and Molecular Life Sciences, 64 (24):3161-3184. [Details]
Duffy, M. J.,O'Donovan, N.,Brennan, D. J.,Gallagher, W. M.,Ryan, B. M.; (2007) 'Survivin: a promising tumor biomarker'. Cancer Lett, 249 (1):49-60. [Details]
O'Brien, S. L.,Fagan, A.,Fox, E. J.,Millikan, R. C.,Culhane, A. C.,Brennan, D. J.,McCann, A. H.,Hegarty, S.,Moyna, S.,Duffy, M. J.,Higgins, D. G.,Jirstrom, K.,Landberg, G.,Gallagher, W. M.; (2007) 'CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer'. Int J Cancer, 120 (7):1434-43. [Details]
O'Brien, S. L.,Fagan, A.,Fox, E. J.,Millikan, R. C.,Culhane, A. C.,Brennan, D. J.,McCann, A. H.,Hegarty, S.,Moyna, S.,Duffy, M. J.,Higgins, D. G.,Jirstrom, K.,Landberg, G.,Gallagher, W. M.; (2007) 'CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer'. Int J Cancer, 120 (7):1434-43. [Details]
Gallagher WM, Lau TY, O'Connor DP, Brennan DJ, Duffy MJ, Pennington SR, ; (2007) 'Breast cancer proteomics: clinical perspectives'. Expert Opinion on Biological Therapy, 2 (NA):209-219. [DOI] [Details]
Smith, FM; Gallagher, WM; Fox, E; Stephens, RB; Rexhepaj, E; Petricoin, EF; Liotta, L; Kennedy, MJ; Reynolds, JV; ; (2007) 'Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy'. Annals of Surgery, 245 (2):259-266. [Details]
Duffy, M. J., O'Donovan, N., Brennan, D. J., Gallagher, W. M., and Ryan, B. M; (2007) 'Survivin: a promising tumor biomarker'. Cancer Letters, 249 (1):49-60. [Details]
Hughes, L., O' Brien, S., and Gallagher, W. M., and McDonnell, S. ; (2007) 'DNA microarray-based transcriptomic profiling of an isogenic cell culture model of breast tumour cell invasion'. Anticancer Research, 27 :1353-1360. [Details]
Rafferty, M., Faller, W. J., Moss, C., McCormick, J., Easty, D. J., and Gallagher, W. M. ; (2007) 'Real-time quantitative reverse transcriptase-polymerase chain reaction analysis of melanoma progression-associated genes'. Anticancer Research, 27 :1301-1308. [Details]
Sallyann L O'brien , Ailís Fagan , Edward J P Fox , Robert C Millikan , Aedín C Culhane , Donal J Brennan , Amanda H McCann , Shauna Hegarty , Siobhan Moyna , Michael J Duffy , Desmond G Higgins , Karin Jirström , Göran Landberg , William M Gallagher ; (2007) 'CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer'. International Journal of Cancer, 120 (7):1426-1435. [Details]
Gallagher WM, Brennan DJ, Kelly C, Rexhepaj E, Dervan PA, Duffy MJ, ; (2007) 'Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer'. Cancer Genomics Proteomics, 3 (NA):121-134. [Details]
Mc Sherry, EA,Mc Goldrick, A,Kay, EW,Hopkins, AM,Gallagher, WM,Dervan, PA; (2007) 'Formalin-fixed paraffin-embedded clinical tissues show spurious copy number changes in array-CGH profiles'. Clinical Genetics, 72 (NA):441-447. [DOI] [Details]
Pennington SR, Collins BC, Clarke A, Kitteringham NR, Gallagher WM, ; (2007) 'Use of proteomics for the discovery of early markers of drug toxicity'. Expert Opinion on Drug Metabolism & Toxicology, 5 (NA):689-704. [DOI] [Details]
Keenan AK, McGillicuddy FC, Lynch I, Rochev YA, Burke M, Dawson KA, Gallagher WM, ; (2006) 'Novel plum pudding gels as potential drug-eluting stent coatings: controlled release of fluvastatin'. Journal of Biomedical Materials Research - Part A, 79 (4):923-933. [DOI] [Details]
Currid, CA,O'Connor, DP,Chang, BD,Gebus, C,Harris, N,Dawson, KA,Dunn, MJ,Pennington, SR,Roninson, IB,Gallagher, WM; (2006) 'Proteomic analysis of factors released from p21-overexpressing tumour cells'. Proteomics, 6 (NA):3739-3753. [DOI] [Details]
Allen, LT; Tosetto, M; Miller, IS; O'Connor, DP; Penney, SC; Lynch, I; Keenan, AK; Pennington, SR; Dawson, KA; Gallagher, WM; ; (2006) 'Surface-induced changes in protein adsorption and implications for cellular phenotypic responses to surface interaction'. Biomaterials, 27 (16):3096-3108. [Details]
Dawson KA, Gallagher WM, Lynch I, Allen LT, Miller I, Penney SC, O'Connor DP, Pennington S, Keenan AK, ; (2006) 'Molecular basis of cell-biomaterial interaction: insights gained from transcriptomic and proteomic studies'. Biomaterials, 27 (35):5871-5882. [DOI] [Details]
Conway, CM; O'Shea, D; O'Brien, S; Lawler, DK; Dodrill, GD; O'Grady, A; Barrett, H; Gulmann, C; O'Driscoll, L; Gallagher, WM; Kay, EW; O'Shea, DG; ; (2006) 'The development and validation of the Virtual Tissue Matrix, a software application that facilitates the review of tissue microarrays on line'. BMC Bioinformatics, 7 (NA). [Details]
McGillicuddy, FC; O'Toole, D; Hickey, JA; Gallagher, WM; Dawson, KA; Keenan, AK; ; (2006) 'TGF-beta 1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by fluvastatin in human coronary artery smooth muscle cells'. Vascular Pharmacology, 44 (6):469-475. [Details]
Lynch, I; Miller, I; Gallagher, WM; Dawson, KA; ; (2006) 'Novel method to prepare morphologically rich polymeric surfaces for biomedical applications via phase separation and arrest of microgel particles'. Journal of Physical Chemistry B, 110 (30):14581-14589. [Details]
Easty, D; Gallagher, W; Bennett, DC; ; (2006) 'Protein tyrosine phosphatases, new targets for cancer therapy'. Current Cancer Drug Targets, 6 (6):519-532. [Details]
Sweeney, N; Gallagher, WM; Muller-Bunz, H; Pampillon, C; Strohfeldt, K; Tacke, M; ; (2006) 'Heteroaryl substituted titanocenes as potential anti-cancer drugs'. Journal of Inorganic Biochemistry, 100 (9):1479-1486. [Details]
Brennan, DJ; Jirstrom, K; Kronblad, A; Millikan, RC; Landberg, G; Duffy, MJ; Ryden, L; Gallagher, WM; O'Brien, SL; ; (2006) 'CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance'. Clinical Cancer Research, 12 (21):6421-6431. [Details]
Duggan, SP; Gallagher, WM; Fox, EJP; Abdel-Latif, MM; Reynolds, JV; Kelleher, D; ; (2006) 'Low pH induces co-ordinate regulation of gene expression in oesophageal cells'. Journal of Carcinogenesis, 27 (2):319-327. [Details]
McGee, S. F., O?Connor, D. P., and Gallagher, W. M.; (2006) 'Functional interrogation of breast cancer: from models to drugs'. Drug Discovery Today, 1 (6):569-584. [Details]
Gallagher, WM,Bergin, OE,Rafferty, M,Kelly, ZD,Nolan, IM,Fox, EJP,Culhane, AC,McArdle, L,Fraga, MF,Hughes, L,Currid, CA,O'Mahony, F,Byrne, A,Murphy, AA,Moss, C,McDonnell, S,Stallings, RL,Plumb, JA,Esteller, M,Brown, R,Dervan, PA,Easty, DJ; (2005) 'Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies'. Carcinogenesis, 26 (NA):1856-1867. [DOI] [Details]
McDonnell, SO,Hall, MJ,Allen, LT,Byrne, A,Gallagher, WM,O'Shea, DF; (2005) 'Supramolecular photonic therapeutic agents'. Journal of the American Chemical Society, 127 (NA):16360-16361. [DOI] [Details]
Gallagher, W. M., Currid, C. A., & Whelan, L. C.; (2005) 'Fibulins and cancer: friend or foe?'. Trends in Molecular Medicine, 11 (7):336-340. [Details]
Lynch, I; Blute, IA; Zhmud, B; MacArtain, P; Tosetto, M; Allen, LT; Byrne, HJ; Farrell, GF; Keenan, AK; Gallagher, WM; Dawson, KA; ; (2005) 'Correlation of the adhesive properties of cells to N-isopropylacrylamide/N-tert-butylacrylamide copolymer surfaces with changes in surface structure using contact angle measurements, molecular simulations, and Raman spectroscopy'. Chemistry of Materials, 17 (15):3889-3898. [Details]
Duffy, M.J., Kelly, Z.D., Culhane, A.C., O'Brien, S., & Gallagher, W.M.; (2005) 'DNA microarray-based gene expression profiling in cancer: aiding cancer diagnosis, assessing prognosis and predicting response to therapy'. Current Pharmacogenomics, 3 :289-304. [Details]
Brennan, DJ; O'Brien, SL; Fagan, A; Culhane, AC; Higgins, DG; Duffy, MJ; Gallagher, WM; ; (2005) 'Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response'. Expert Opinion on Biological Therapy, 5 (8):1069-1083. [Details]
Rehmann, FJK; Rous, AJ; Mendoza, O; Sweeney, NJ; Strohfeldt, K; Gallagher, WM; Tacke, M; ; (2005) 'A trimethoxyphenyl substituted ansa-titanocene: A possible anti-cancer drug'. Polyhedron, 24 (11):1250-1255. [Details]
Gallagher, W.M., Allen, L.T., O'Shea, C., Kenna, T., Hall, M., Gorman, A., Killoran, J., and O'Shea, D.F.; (2005) 'A potent non-porphyrin class of photodynamic therapeutic agent: cellular localisation, cytotoxic potential and influence of hypoxia'. BRITISH JOURNAL OF CANCER, 92 (9):1702-1710. [Details]
Kavanagh, CA; Gorelova, TA; Selezneva, II; Rochev, YA; Dawson, KA; Gallagher, WM; Gorelov, AV; Keenan, AK; ; (2005) 'Poly(N-isopropy acrylamide) copolymer films as vehicles for the sustained delivery of proteins to vascular endothelial cells'. Journal of Biomedical Materials Research - Part A, 72A (1):25-35. [Details]
Rehmann, FJK; Cuffe, LP; Mendoza, O; Rai, DK; Sweeney, N; Strohfeldt, K; Gallagher, WM; Tacke, M; ; (2005) 'Heteroaryl substituted ansa-titanocene anti-cancer drugs derived from fulvenes and titanium dichloride'. Applied Organometallic Chemistry, 19 (3):293-300. [Details]
Tacke, M,Cuffe, LP,Gallagher, WM,Lou, Y,Mendoza, O,Muller-Bunz, H,Rehmann, FJK,Sweeney, N; (2004) 'Methoxy-phenyl substituted ansa-titanocenes as potential anti-cancer drugs derived from fulvenes and titanium dichloride'. Journal of Inorganic Biochemistry, 98 (NA):1987-1994. [DOI] [Details]
Kavanagh, CA; Rochev, YA; Gallagher, WA; Dawson, KA; Keenan, AK; ; (2004) 'Local drug delivery in restenosis injury: thermoresponsive co-polymers as potential drug delivery systems'. Pharmacology and Therapeutics, 102 (1):1-15. [Details]
Tacke, M; Allen, LT; Cuffe, L; Gallagher, WM; Ying, L; Mendoza, O; Muller-Bunz, H; Rehmann, FJK; Sweeney, N; ; (2004) 'Novel titanocene anti-cancer drugs derived from fulvenes and titanium dichloride'. Organometallic Chemistry, 689 (13):2242-2249. [Details]
McArdle, L; McDermott, M; Purcell, R; Grehan, D; O'Meara, A; Breatnach, F; Catchpoole, D; Culhane, AC; Jeffery, I; Gallagher, WM; Stallings, RL; ; (2004) 'Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q'. Journal of Carcinogenesis, 25 (9):1599-1609. [Details]
Gorman, A,Killoran, J,O'Shea, C,Kenna, T,Gallagher, WM,O'Shea, DF; (2004) 'In vitro demonstration of the heavy-atom effect for photodynamic therapy'. Journal of the American Chemical Society, 126 (NA):10619-10631. [DOI] [Details]
Allen, LT; Fox, EJP; Blute, I; Kelly, ZD; Rochev, Y; Keenan, AK; Dawson, KA; Gallagher, WM; ; (2003) 'Interaction of soft condensed materials with living cells: Phenotype/transcriptome correlations for the hydrophobic effect'. Proceedings of the National Academy of Sciences of the United States of America, 100 (11):6331-6336. [Details]
Greene, L. M., Twal, W. O., McDermott, E. W., Hill, A. D., O Higgins, N. J., McCann, A. H., Dervan, P. A., Duffy, M. J., Argraves, W. S., and Gallagher, W. M.; (2003) 'Elevated expression and altered processing of fibulin-1 protein in human breast cancer'. British Journal of Cancer, 88 (6):871-878. [Details]
Wilson, S. W., Gorelov, A., Rochev, Y., McGillicuddy, F., Dawson, K. A., Gallagher, W. M., and Keenan, A. K.; (2003) 'Extended delivery of the anti-mitotic agent colchicines from thermoresponsive N-isopropylarcylamide-based co-polymer films to human vascular smooth muscle cells'. Journal of Biomedical Materials Research, 67A (2):667-673. [Details]
Wilson, SJ; Gorelov, AV; Rochev, YA; McGillicuddy, F; Dawson, KA; Gallagher, WM; Keenan, AK; ; (2003) 'Extended delivery of the antimitotic agent colchicine from thermoresponsive N-isopropylacrylamide-based copolymer films to human vascular smooth muscle cells'. Journal of Biomedical Materials Research - Part A, 67A (2):667-673. [Details]
Doorty, KB; Golubeva, TA; Gorelov, AV; Rochev, YA; Allen, LT; Dawson, KA; Gallagher, WM; Keenan, AK; ; (2003) 'Poly(N-isopropylacrylamide) co-polymer films as potential vehicles for delivery of an antimitotic agent to vascular smooth muscle cells'. Cardiovascular Pathology, 12 (2):105-110. [Details]
Argraves, WS; Greene, LM; Cooley, MA; Gallagher, WM; ; (2003) 'Fibulins: physiological and disease perspectives'. EMBO Reports, 4 (12):1127-1131. [Details]
Killoran, J,Allen, L,Gallagher, JF,Gallagher, WM,O'Shea, DF; (2002) 'Synthesis of BF2 chelates of tetraarylazadipyrromethenes and evidence for their photodynamic therapeutic behaviour'. Chemical Communications, -1 (17):1862-1863. [DOI] [Details]
Doorty, KB; Golubeva, T; Gorelov, A; Rochev, Y; Dawson, K; Gallagher, WM; Keenan, AK; ; (2001) 'Investigation of co-polymer films as drug delivery systems for prevention of vascular smooth muscle cell proliferation'. British Journal of Pharmacology, 134 (NA). [Details]
Gallagher, W. M., Greene, L. M., Ryan, M. P., Sierra, V., Berger, A., Laurent-Puig, P., and Conseiller, E.; (2001) 'Human fibulin-4: analysis of its biosynthetic processing and mRNA expression in normal and tumour tissue'. FEBS Letters, 489 (1):59-66. [Details]
Rochev, Y., Golubeva, T., Gorelov, A., Allen, L., Gallagher, W. M., Selezneva, I., Gavrilyuk, B., and Dawson, K.; (2001) 'Surface modification for controlled cell growth on co-polymers of N-isopropylacrylamide'. Progress in Colloid and Polymer Science, 118 :153-156. [Details]
Gallagher, W. M., Greene, L. M., Allen, L. T., Strachan, S. M., Rochev, Y., Dawson, K. A., Ryan, M. P., and Conseiller, E.; (2001) 'Contemporary strategies for cancer therapy: the p53 gene as a paradigm. [Not indexed in JCR; ISBN 92-894-1575-4: Also available via http://www.mariecurie.org/annals/]'. The Annals of the Marie Curie Fellowships, 1 :106-111. [Details]
Gallagher, W. M., and Brown, R.; (1999) 'p53-oriented cancer therapies: current progress'. Annals of Oncology, 10 :139-150. [Details]
Gallagher, W. M., Argentini, M., Sierra, V., Bracco, L., Debussche, L., and Conseiller, E.; (1999) 'MBP1: a novel mutant p53-specific protein partner with oncogenic properties'. Oncogene, 18 :3608-3616. [Details]
Brown, R., Hirst, G. L., Gallagher, W. M., McIlwrath, A. J., Margison, G. P., van der Zee, A. G. J., and Anthoney, D. A.; (1997) 'hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents'. Oncogene, 15 :42-52. [Details]
Gallagher, W. M., Cairney, M., Schott, B., Roninson, I. B., and Brown, R.; (1997) 'Identification of p53 genetic suppressor elements which confer resistance to cisplatin'. Oncogene, 14 :185-193. [Details]
Anthoney, D. A., McIlwrath, A. J., Gallagher, W. M., Edlin, A. R., and Brown, R.; (1996) 'Microsatellite instability, apoptosis and loss of p53 function in drug-resistant tumor cells'. Cancer Research, 56 :1374-1381. [Details]
Gallagher, W. M., and Grant, G. H.; (1996) 'Structural basis of p21H-ras molecular switch inhibition by a neutralizing antibody'. Journal of Molecular Graphics, 14 (1):42-50. [Details]
                                                                                             

Research

Research Interests

A major focus of the Cancer Biology and Therapeutics (CBT) Lab, led by Prof. Gallagher, is the identification and validation of molecular determinants of tumour progression in breast cancer and melanoma (www.cbtlab.ie ). We also have a particular interest in the identification and validation of candidate prognostic and predictive biomarkers in oncology, with emphasis on the translation of transcriptomic and proteomic datasets into clinically relevant assays. In addition, our team utilises lentiviral-based approaches to investigate the functional relevance of candidate tumour progression associated genes at both in vitro  and in vivo  levels, as well as engage in preclinical evaluation of novel anti-cancer agents. In this respect, we currently co-ordinate an advanced Molecular Imaging Facility, comprised of state-of-the-art optical (IVIS Spectrum) and radionuclide (PET/CT and SPECT/CT) in vivo imaging systems.
 
The CBT Lab participates in the national cancer research initiative: The Irish Cancer Society Collaborative Cancer Research Centre BREAST-PREDICT, of which Prof. Gallagher is Director. The translational activities within the Centre owe their origins in significant part to two Science Foundation Ireland-funded programmes, namely Molecular Therapeutics for Cancer Ireland (www.mtci.ie) with Prof. Gallagher as a co-PI and Deputy Co-ordinator, and Systems Biology Ireland (www.ucd.ie/sbi) led by Prof. Walter Kolch. Our team also co-ordinates an FP7 Collaborative Research programme, RATHER  (www.ratherproject.com ), which is focused on providing rationalised therapy options for difficult-to-treat breast cancer subtypes, namely triple negative (TN) breast cancer and invasive lobular carcinoma (ILC). This collaborative project, which involves 8 academic and industrial partners across 5 EU countries, centres on detailed molecular analysis of kinome alterations at multiple levels (gene sequence mutations, copy number variation, mRNA expression, phosphorylation status) in these two subtypes of breast cancer. Together with functional interrogation of lead kinase targets identified from this molecular analysis, the research programme involves the development and utilisation of novel companion diagnostic assays in a clinical trials context.

The CBT lab under the direction of Prof Gallagher, co-ordinates an FP7 Marie Curie Industry-Academia Partnership and Pathways (IAPP) Programme under FP7 SYS-MEL (www.sysmel.com), which is focused on developing prognostic and predictive tests for melanoma, the most aggressive form of skin cancer. This programme involves 6 partners (4 academic/2 industrial) across 3 EU countries and runs from 2013-2017. This SYS-MEL Consortium was a follow-up from the successful TargetMelanoma project that was completed in June 2013.